Results 31 to 40 of about 2,342,069 (298)

Downregulation of VPS13C promotes cisplatin resistance in cervical cancer by upregulating GSTP1

iScience, 2023
Summary: Cisplatin resistance remains a major obstacle limiting the effectiveness of chemotherapy in cervical cancer. However, the underlying mechanism of cisplatin resistance is still unclear.
Xiangyu Tan, Xueqian Wang, Xueyao Liao, Xin Wang, Zhichao Jiang, Wenjia Liang, Chen Cao, Danni Gong, Zheng Hu, Xun Tian   +9 more
doaj   +1 more source

EBV-Driven ODC1 Upregulation Enhances Polyamine Anabolism to Promote Viral Replication and Cisplatin Resistance in Nasopharyngeal Carcinoma. [PDF]

Adv Sci (Weinh)
EBV‑BZLF1 initiates ODC1‑driven polyamine anabolism that correlates with poor clinical prognosis in nasopharyngeal carcinoma. The ODC1–spermidine axis promotes viral replication, cell proliferation and innate immune evasion. Pharmacological inhibition of ODC1 rescues cisplatin sensitivity, establishing ODC1 as a viable therapeutic target for EBV ...
Li Y, Hu X, Yang C, Liu N, Wang L, Cai X, Tang M, Cao Y, Shang L, Shi F.   +9 more
europepmc   +2 more sources

Regrowth resistance: low-level platinum resistance mediated by rapid recovery from platinum-induced cell-cycle arrest [PDF]

, 2009
The H69CIS200 and H69OX400 cell lines are novel models of low-level platinum drug resistance developed from H69 human small cell lung cancer cells with eight 4-day treatments of 200 ng/ml cisplatin or 400 ng/ml oxaliplatin respectively. A recovery period
Ross Davey, Davey, Ross, Britta Stordal, Stordal, Britta   +3 more
core   +2 more sources

TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway

Nature Communications, 2023
Cisplatin resistance along with chemotherapy-induced neuropathic pain is an important cause of treatment failure for many cancer types and represents an unmet clinical need.
Se Jin Oh, Ji Yeon Lim, Min Kyu Son, Jun Hyeok Ahn, Kwon-Ho Song, Hyo-Jung Lee, Suyeon Kim, Eun Ho Cho, Joon-Yong Chung, Hanbyoul Cho, Hyosun Kim, Jae-Hoon Kim, Jooyoung Park, Jungmin Choi, Sun Wook Hwang, Tae Woo Kim   +15 more
doaj   +1 more source

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance

Thoracic Cancer, 2021
Background: Acquired resistance of chemotherapy, especially cisplatin, is a major challenge in lung cancer treatment. We conducted this study to examine whether a cyclin D kinase 4/6 (CDK4/6) inhibitor, PD 0332991, could reverse cisplatin resistance in ...
Minghui Liu, Liyuan Cui, Xin Li, Chunqiu Xia, Yongwen Li, Rui Wang, Fan Ren, Hongyu Liu, Jun Chen   +8 more
doaj   +1 more source

Transforming Growth Factor Alpha Stimulation of Mucosal Tissue Cultures from Head and Neck Squamous Cell Carcinoma Patients Increases Chemoresistance to Cisplatin [PDF]

, 2010
The monoclonal epidermal growth factor receptor ( EGFR) antibody cetuximab (Erbitux(TM)) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination ...
Baumeister, Philipp, Ulrich Harréus, Schwenk-Zieger, Sabina, Maximilian Reiter, Philipp Baumeister, Reiter, Maximilian, Sabina Schwenk-Zieger, Harreus, Ulrich   +7 more
core   +1 more source

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

Molecular Cancer, 2022
Purpose The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance.
Zhen-duo Shi, Lin Hao, Xiao-xiao Han, Zhuo-Xun Wu, Kun Pang, Yang Dong, Jia-xin Qin, Guang-yue Wang, Xuan-ming Zhang, Tian Xia, Qing Liang, Yan Zhao, Rui Li, Shao-qi Zhang, Jun-hao Zhang, Jian-gang Chen, Gong-cheng Wang, Zhe-Sheng Chen, Cong-hui Han   +18 more
doaj   +1 more source

Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line

BMC Cancer, 2006
Background Cisplatin is widely used for chemotherapy of head and neck squamous cell carcinoma. However, details of the molecular mechanism responsible for cisplatin resistance are still unclear.
Zhang Ping, Zhang Zhiyuan, Zhou Xiaojian, Qiu Weiliu, Chen Fangan, Chen Wantao   +5 more
doaj   +1 more source

Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance [PDF]

ChemMedChem, 2014
AbstractCyclooxygenase (COX) is an enzyme involved in tumorigenesis and is associated with tumor cell resistance against platinum‐based antitumor drugs. Cisplatin analogues were conjugated with COX inhibitors (indomethacin, ibuprofen) to study the synergistic effects that were previously observed in combination treatments.
Wilma, Neumann, Brenda C, Crews, Menyhárt B, Sárosi, Cristina M, Daniel, Kebreab, Ghebreselasie, Matthias S, Scholz, Lawrence J, Marnett, Evamarie, Hey-Hawkins   +7 more
openaire   +2 more sources

Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness

Thoracic Cancer, 2020
Background Lung cancer is the leading cause of cancer death and is commonly treated by cisplatin. Although cisplatin treatment may initially be successful, its effectiveness usually reduces significantly in disease‐recurrent patients.
Maoyuan Zhao, Ting Wang, Zhouguang Hui
doaj   +1 more source